Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

To 'Post Your News' use the button at the top right.

Immunocore’s IMCgp100 Receives Promising Innovative Medicine (PIM) Designation Under UK Early Access to Medicines Scheme (EAMS) for the Treatment of Patients with Uveal Melanoma

Immunocore Limited, the world’s leading TCR company focused on delivering first-in-class biological therapies that transform lives, today announces that it has been informed by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) that IMCgp100 has been granted Promising Innovative Medicines (PIM) designation for the treatment of patients with metastatic uveal melanoma.

Read the rest of entry »

Global Business Accelerator Programme Cell and Gene Therapy - Innovate UK organising visit to Japan

The Enterprise Europe Network (EEN), in partnership with Innovate UK is organising a funded Accelerator Programme visit to Japan for innovative UK companies operating in the Cell and Gene Therapy sector.

Read the rest of entry »

Leading biotech Immunocore expands to The Oxford Science Park

Oxford, UK:  Immunocore Limited, the world’s leading TCR company focused on delivering first-in-class biological therapies that transform lives, has taken laboratory and office space at The Oxford Science Park. In its new premises on the Park, Immunocore will be focused on the development of immunotherapies for infectious diseases, complementing its cancer research at Milton Park in Oxford

Read the rest of entry »

Wessex Academic Health Science Network and Wessex Clinical Research Network launch their Technology Support Programme (Round 1)

Wessex Clinical Research Network (CRN) and Wessex Academic Health Science Network (AHSN) have teamed up to support commercial innovators gather crucial evidence on their products.  Their new Technology Support Programme (TSP) will help companies to access the NHS’s research infrastructure to obtain high quality evidence on the economic and health gains their products can bring.

Read the rest of entry »

Arecor Announces Successful Vaccine Stabilising Formulation Technology to More Effectively Combat Two Major Diseases of Livestock in the Developing World

Arecor and its partner, non-profit company, Global Alliance for Livestock Veterinary Medicines (GALVmed), have successfully stabilised liquid formulations of vaccines to combat two major diseases of livestock across the developing world including Africa, Asia and the Middle East In this work, the ArestatTM technology has been applied to enable a vaccine to be distributed pre-prepared in a liquid format without the requirement for in-field reconstitution from the freeze-dried powder form ArestatTM technology has also been applied to reduce the cost of a batch of vaccine diluent by 96 per cent., thereby improving its distribution and uptake by farmers Arecor’s formulation technology work has been supported by Innovate UK through UK aid of the UK government and the Bill & Melinda Gates Foundation Cambridge, UK., 8th December 2017: Arecor Ltd (“the Company”),  a leader in developing superior biopharmaceuticals through the application of an innovative formulation technology ...

Read the rest of entry »

Oxford MEStar wins grant support to work with CGT Catapult and AK Biomedical as part of Jiangsu-UK industrial challenge programme

Oxford MESTar, in collaboration with the Cell and Gene Therapy Catapult and AK Biomedical, has won a grant from Innovate UK to support the development of a novel manufacturing system intended to dramatically reduce the cost of production of CAR-T therapies.

Read the rest of entry »

Summit Therapeutics to Report Financial Results for the Third Quarter And Nine Months Ended 31 October 2017 On 6 December 2017

Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, will announce its financial results for the third quarter and nine months ended 31 October 2017 on 6 December 2017. About Summit Therapeutics Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at and Summit can be followed on Twitter (@summitplc). For more information, please contact: Summit     Glyn Edwards / Richard Pye (UK office) Tel: 44 (0)1235 443 951 ...

Read the rest of entry »

Activate Science has been all over Europe

Activate Science, an annual event series organised by Thermo Fisher Scientific and attended by laboratory personnel across Europe, reached delegates at 28 customer sites in 2017.

Read the rest of entry »

Cryopreservation of Hematopoietic Stem Cells

HSC-BANKER® from AMSBIO is a new optimised GMP grade cryopreservation medium for the banking of hematopoietic stem cellsisolated from umbilical cord blood, peripheral blood and bone marrow.    


Read the rest of entry »

BioHub Birmingham® expands to meet demand for incubator space

The BioHub Birmingham®, which provides flexible laboratory space for pre-revenue life science companies, has announced its expansion to meet the growing demand for laboratory space in the Midlands.

Read the rest of entry »

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.

OBN Noticeboard

This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc.  Just drop an email to us,, and we will post.